Effects of the cholecystokinin receptor antagonist L-364,718 on experimental pancreatitis in mice.
The effects of the cholecystokinin receptor antagonist L-364,718 was studied in a model of mild pancreatitis induced in mice by repeated injections of the secretagogue caerulein and in a lethal form of pancreatitis induced by feeding mice an ethionine-supplemented choline-deficient diet. L-364,718 prevented the caerulein-induced rise in serum amylase and pancreatic weight in a dose-dependent manner, the most effective dose being 0.1 mg/kg body wt. L-364,718 also prevented the caerulein-induced pancreatic inflammation as seen by light microscopy. L-364,718 offered no protective effects as determined by changes in serum amylase, pancreatic weight, histology, or mortality in the ethionine-supplemented choline-deficient diet model.
Silverman
M
M
Division of Gastroenterology, Long Island Jewish Medical Center, New Hyde Park, New York.
Ilardi
C
C
Bank
S
S
Kranz
V
V
Lendvai
S
S
D000681:Amylases / Q000097:blood; D000818:Animals; D001570:Benzodiazepinones / Q000494:pharmacology*; D002108:Ceruletide; D002766:Cholecystokinin / Q000037:antagonists & inhibitors*; D002796:Choline Deficiency / Q000150:complications; D020109:Devazepide; D005001:Ethionine; D008297:Male; D051379:Mice; D009929:Organ Size; D010179:Pancreas / Q000473:pathology; D010195:Pancreatitis / Q000139:chemically induced / Q000201:enzymology / Q000473:pathology*; D011949:Receptors, Cholecystokinin / Q000187:drug effects*
D001570:Benzodiazepinones; D011949:Receptors, Cholecystokinin; D002108:Ceruletide; D002766:Cholecystokinin; D000681:Amylases; D020109:Devazepide; D005001:Ethionine